Anti-Human Angiopoietin-like Protein 3/ANGPTL3 Reference Antibody (Evinacumab, RUO) (HV176016)

Name: Anti-Human Angiopoietin-like Protein 3/ANGPTL3 Reference Antibody (Evinacumab, RUO)
Brand: abinScience
SKU: HV176016
Price: 176 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	HV176016
Description	Evinacumab (HV176016) is a research-grade recombinant antibody targeting ANG-5. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactivité des espèces	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Espèce hôte	Human
Clonalité	Monoclonal
Isotype	IgG4-kappa
Système d'expression	Mammalian cells
Cible	ANG-5, Angiopoietin-like protein 3, ANGPT5, Angiopoietin-5, ANGPTL3, Angiopoietin-related protein 3
Niveau d'endotoxines	< 10 EU/mg
Pureté	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Numéro d'accès	Q9Y5C1
Forme	Liquid
Tampon de stockage	0.01M PBS pH 7.4 Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Noms alternatifs	REGN1500, 1446419-85-7
Contexte	Angiopoietin-related protein 3 (ANGPTL3) is a ~53 kDa protein. Acts in part as a hepatokine that is involved in regulation of lipid and glucose metabolism. Proposed to play a role in the trafficking of energy substrates to either storage or oxidative tissues in response to food intake. Has a stimulatory effect on plasma triglycerides (TG), which is achieved by suppressing plasma TG clearance via inhibition of LPL activity. The inhibition of LPL activity appears to be an indirect mechanism involving recruitment of proprotein convertases PCSK6 and FURIN to LPL leading to cleavage and dissociation of LPL from the cell surface; the function does not require ANGPTL3 proteolytic cleavage but seems to be mediated by the N-terminal domain, and is not inhibited by GPIHBP1. Can inhibit endothelial lipase, causing increased plasma levels of high density lipoprotein (HDL) cholesterol and phospholipids. 1. Koishi, R. et al. (2002) Nature genetics 30, 151-7. PMID: 11788823 2. Ono, M. et al. (2003) The Journal of biological chemistry 278, 41804-9. PMID: 12909640 3. Robciuc, MR. et al. (2013) Arteriosclerosis, thrombosis, and vascular biology 33, 1706-13. PMID: 23661675 4. Tikka, A. et al. (2014) Bioscience reports 34, e00160. PMID: 25495645 5. Shimizugawa, T. et al. (2002) The Journal of biological chemistry 277, 33742-8. PMID: 12097324 6. Lee, EC. et al. (2009) The Journal of biological chemistry 284, 13735-13745. PMID: 19318355 7. Liu, J. et al. (2010) The Journal of biological chemistry 285, 27561-70. PMID: 20581395 8. Shimamura, M. et al. (2007) Arteriosclerosis, thrombosis, and vascular biology 27, 366-72. PMID: 17110602 9. Shan, L. et al. (2009) The Journal of biological chemistry 284, 1419-24. PMID: 19028676 10. Shimamura, M. et al. (2003) Biochemical and biophysical research communications 301, 604-9. PMID: 12565906
Note	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507)